599 related articles for article (PubMed ID: 17006377)
1. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
[TBL] [Abstract][Full Text] [Related]
2. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.
Bouchard P; Panay N; de Villiers TJ; Vincendon P; Bao W; Cheng RJ; Constantine G
Climacteric; 2012 Feb; 15(1):12-20. PubMed ID: 22066790
[TBL] [Abstract][Full Text] [Related]
3. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
Simon JA;
Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
[TBL] [Abstract][Full Text] [Related]
4. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA;
BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496
[TBL] [Abstract][Full Text] [Related]
5. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial.
Simon JA; Bouchard C; Waldbaum A; Utian W; Zborowski J; Snabes MC
Obstet Gynecol; 2007 Mar; 109(3):588-96. PubMed ID: 17329509
[TBL] [Abstract][Full Text] [Related]
6. A 12-week clinical trial determining the efficacy of synthetic conjugated estrogens, A (SCE), in the treatment of vasomotor symptoms in menopausal women.
Stevens RE; Hanford K; Wason S; Cusack SL; Phelps KV
Int J Fertil Womens Med; 2000; 45(4):264-72. PubMed ID: 10997482
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
Speroff L; Gass M; Constantine G; Olivier S;
Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms.
Speroff L; Haney AF; Gilbert RD; Ellman H;
Menopause; 2006; 13(3):442-50. PubMed ID: 16735941
[TBL] [Abstract][Full Text] [Related]
9. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
[TBL] [Abstract][Full Text] [Related]
10. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety.
Archer DF; Dupont CM; Constantine GD; Pickar JH; Olivier S;
Am J Obstet Gynecol; 2009 Mar; 200(3):238.e1-238.e10. PubMed ID: 19167693
[TBL] [Abstract][Full Text] [Related]
11. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women.
Hedrick RE; Ackerman RT; Koltun WD; Halvorsen MB; Lambrecht LJ
Menopause; 2009; 16(1):132-40. PubMed ID: 18971794
[TBL] [Abstract][Full Text] [Related]
12. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
[TBL] [Abstract][Full Text] [Related]
13. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.
Pinkerton JV; Constantine G; Hwang E; Cheng RF;
Menopause; 2013 Jan; 20(1):28-37. PubMed ID: 23010882
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause.
Archer DF; Seidman L; Constantine GD; Pickar JH; Olivier S
Am J Obstet Gynecol; 2009 Feb; 200(2):172.e1-10. PubMed ID: 19110224
[TBL] [Abstract][Full Text] [Related]
15. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
Bachmann G; Bobula J; Mirkin S
Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women.
Hudita D; Posea C; Ceausu I; Rusu M
Eur Rev Med Pharmacol Sci; 2003; 7(5):117-25. PubMed ID: 15214586
[TBL] [Abstract][Full Text] [Related]
17. Identifying meaningful differences in vasomotor symptoms among menopausal women.
Wyrwich KW; Spratt DI; Gass M; Yu H; Bobula JD
Menopause; 2008; 15(4 Pt 1):698-705. PubMed ID: 18369313
[TBL] [Abstract][Full Text] [Related]
18. Micro-dose transdermal estradiol for relief of hot flushes in postmenopausal Asian women: a randomized controlled trial.
Haines C; Yu SL; Hiemeyer F; Schaefers M
Climacteric; 2009 Oct; 12(5):419-26. PubMed ID: 19479489
[TBL] [Abstract][Full Text] [Related]
19. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Menopause; 2009; 16(5):877-82. PubMed ID: 19458560
[TBL] [Abstract][Full Text] [Related]
20. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L
Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
